Innovative, women's health drug development company featuring two drug delivery platforms developed by Robert Langer, PhD/MIT including a technology-enabled drug delivery implant supported by the Bill & Melinda Gates FoundationCommercial Strategy• Develop, deliver, and maintain the company's overall commercial strategy utilizing integrated insights, quantitative and qualitative analyses to drive a cohesive go-to-market strategy at the product, brand, and portfolio level➣Leading the cross-company pre-market planning process including market insights, KOL mapping, competitive/landscape analysis, payer research and HCP/patient segmentation and journey. ➣Develop and maintain launch planning playbook to support brand activation across all key stakeholders optimizing digital, in-person, CME/Symposia and non-personal promotional activities. ➣Leading the commercial alliance management efforts supporting the global launch of XACIATO. ➣Steering cross-functional Initiatives including brand messaging, positioning, HCP segmentation, GTN/pricing analysis and optimization, omnichannel, and payer marketing

Business & Corporate Development• Driving transactions with top tier women’s health companies (Bayer and Merck/Organon)• Facilitated end-to-end deal development and execution ➣ Transformational reproductive health transaction with a total deal value of $310 million including commercial milestone payments plus tiered royalties on net sales. • Secured global partnership for recently approved anti-infective product (XACIATO).➣The total deal value of up to $182.5 million, including a $10 million upfront payment and tiered double-digit royalties based on net sales Capital Raising > $150 million in new capital • Co-led efforts to secure first-of-its-kind $50 million grant funding • Active participant and presenter at medical congresses, industry partnership and investor events

Collaborated with founders, lead investors, and the Board of Directors to establish a stand-alone specialty pharmaceutical entity. Led the newly separated entity Evofem LLC entity, creating stand-alone operational and commercial capabilities. Drove initiatives in strategic commercial / launch planning (focused on HCP, Payer and Patient pull through), commercial talent acquisition (recruiting and hiring top-tier commercial talent to lead the US & RoW business units), portfolio optimization (LCM/R&D planning), operations (new manufacturing facility and qualification of API), new business development and fundraising presentations (including conferences and non-deal / IPO roadshows). • Maintained P&L responsibility for standalone commercial team including sales and marketing leadership, field sales, market access, market research, supply, distribution, and commercial operations• Drove all the market and brand planning and launch preparation for the women’s health franchise targeting specialty HCPs through in-person and non-personal (digital) promotion, and other core stakeholders including Payers, KOLs, and advocacy groups.• Organized the business around 3 Rx products; 5 indications driving an independent valuation of >$1B.• Co-Raised >$80 million in institutional financing.

During my tenure, we relaunched the company, drove and delivered double-digit top and bottom-line profitability and had a successful exit via M&A (Aegis/Synovate).